Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 464 across all filing types
Latest filing 2021-11-17 Board/Management Inform…
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Resignation
Board/Management Information Classification · 100% confidence The document is a certified true copy of a board resolution regarding the resignation of a company secretary and compliance officer. It is a formal announcement of a change in senior management personnel. There are no financial statements, earnings data, or regulatory filings referenced. The content fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2021-11-17 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from LASA Supergenerics Limited dated November 14, 2021, reporting the outcome of a Board Meeting. It includes the approval of unaudited financial results for the quarter and six months ended September 30, 2021, along with a limited review report from the statutory auditor. The document also announces management changes, specifically the resignation and appointment of the Company Secretary and Compliance Officer. The financial results include detailed income statements, balance sheets, and notes explaining the financial performance and exceptional items. The presence of unaudited financial results for a quarter and half-year period, along with detailed financial statements and notes, indicates this is a comprehensive interim/quarterly financial report. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2022
2021-11-14 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying about the preponement (rescheduling to an earlier date) of a Board Meeting originally scheduled for November 15, 2021, now moved to November 14, 2021. The purpose of the meeting is to consider and approve unaudited financial results for the quarter and half year ended September 30, 2021, along with a limited review report. It also mentions the closure of the trading window pursuant to SEBI regulations. The document does not contain any financial data or results itself, nor does it include the actual financial statements or reports. It is an announcement regarding the scheduling of a board meeting and related compliance matters. The document length is short (1958 characters), and it serves as an intimation rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory announcements and compliance notifications that do not fit other specific categories.
2021-11-11 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges about an upcoming Board Meeting scheduled to consider and approve unaudited financial results for the quarter and half year ended September 30, 2021. It is an intimation of the meeting date and agenda, not the financial results report itself. The document length is only 1780 characters, indicating it is a brief announcement rather than a full report. It also references regulatory compliance with SEBI regulations and trading window closure. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain actual financial data or detailed report content.
2021-11-08 English
Reply to Clarification Sought
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited, providing a clarification under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It responds to a query about expected revenue loss due to a disruption until restart from authorities. The content is a regulatory disclosure or clarification rather than a full financial report, earnings release, or management discussion. The document length is short (1186 characters) and it is a formal regulatory communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and clarifications that do not fit other specific categories.
2021-10-21 English
Updates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about a temporary stoppage of manufacturing activities due to an order from the Maharashtra Pollution Control Board and mentions ongoing legal action. The content is an operational update related to regulatory compliance and business interruption, not a financial report, audit, earnings release, or any other detailed report. It is a regulatory announcement informing the market about a material event affecting the company. The document length is short (1942 characters) and it does not contain financial data or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-18 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.